--- title: "Zai Lab desk view: Zai Lab's future now runs through one DLL3 drug" url: "https://aibio.space/companies/zai-lab/desk-view/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-31" tickers: "HKEX:9688" summary: "The China portfolio is finding a floor after price cuts. Zoci's first-line data at ESMO and its 2027 phase 3 interim will decide whether Zai Lab becomes a…" --- Opinion Desk view by the aibio.space Zai desk. Updated October 22, 2026. Every figure links to its source. This is analysis, not a recommendation to trade. [How desk views are written](https://aibio.space/disclosures/). Zai Lab · Opinion 2026-10-22 # Zai Lab's future now runs through one DLL3 drug The China portfolio is finding a floor after price cuts. Zoci's first-line data at ESMO and its 2027 phase 3 interim will decide whether Zai Lab becomes a global developer. ## The technology Zai Lab has two businesses. The first is a China commercial portfolio built on in-licensed drugs: [ZEJULA, VYVGART, NUZYRA, OPTUNE, QINLOCK, XACDURO, AUGTYRO and KarXT](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/zlab-20260630.htm), plus TIVDAK, approved for cervical cancer in June. It sells them in Greater China. The second is a global pipeline of its own. The lead is zoci (zocilurtatug pelitecan), an antibody-drug conjugate aimed at DLL3 on small cell lung cancer cells. In previously treated patients it produced a [68% response rate at 1.6 mg/kg](https://www.businesswire.com/news/home/20251024903169/en/) in 19 second-line patients, and a 62.5% intracranial response rate in patients with brain metastases at AACR 2026. Behind it is ZL-1503, a long-acting IL-13/IL-31 bispecific for atopic dermatitis, with [first human data due in the second half of 2026](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm). ## The odds Zoci's phase 3, DLLEVATE, compares it with investigator's choice of single-agent therapy in about [665 previously treated patients](https://www.businesswire.com/news/home/20251024903169/en/) according to Zai Lab (the ClinicalTrials.gov entry estimates 480), with response rate as the interim endpoint and overall survival as the final one. Response-based interim analyses can support accelerated approval, and Zai Lab is targeting a U.S. submission in 2027. Industry data put the chance of a phase 3 solid tumor program reaching an application at [42.9%](https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf). The bigger prize is first-line SCLC, where zoci is still in phase 1 with atezolizumab and carboplatin. Data are due at ESMO on [October 26](https://www.businesswire.com/news/home/20260929210432/en/Zai-Lab-to-Present-First-Global-Data-from-Clinical-Trial-Evaluating-Zocilurtatug-Pelitecan-Zoci-As-First-Line-Treatment-for-Extensive-Stage-Small-Cell-Lung-Cancer-ES-SCLC). ZL-1503 is in a phase 1/1b study, with initial data from atopic dermatitis patients [expected in the first half of 2027](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm); drugs at that stage reach approval about [7.9% of the time](https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf) on average. ## The money Cash, cash equivalents, short-term investments and current restricted cash were [$717.5 million at June 30, 2026](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm), down from $789.6 million at the end of 2025. Short-term debt was [$238.1 million](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/zlab-20260630.htm). The second-quarter net loss was $50.8 million on revenue of $106.3 million. Research spending rose to [$61.8 million](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm) from $50.6 million a year earlier, mostly on licensing fees, while SG&A stayed near $73 million. Vertex, a partner, has an [FDA decision date of November 30, 2026](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm) for povetacicept in IgA nephropathy. Zai Lab took part in the global trial in Greater China, but the filings reviewed do not describe its rights to the drug. Zai Lab's [10-Q says cash should cover operating needs for at least the next 12 months](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/zlab-20260630.htm). It says it maintained commercial profitability in the second quarter and expects a [return to meaningful growth in 2027](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm). ## The risks China pricing policy is the clearest risk. ZEJULA sales fell after [volume-based procurement for generic olaparib](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/zlab-20260630.htm), and VYVGART after a price cut tied to NRDL renewal. New launches like KarXT and TIVDAK face the same reimbursement process. The second risk is concentration in zoci, which carries most of the global story. The third is leadership: president and COO Josh Smiley [left in May](https://www.sec.gov/Archives/edgar/data/1704292/000162828026037387/zlab-20260518.htm), and his duties went to the CEO and others. ## Our read Zai Lab is in a transition from China licensor to global developer, and the two halves are moving at different speeds. The China business is stabilizing after a hard first quarter but will not grow meaningfully until 2027 on the company's own guidance. Zoci is the reason to pay attention, with strong early response data and a phase 3 that is enrolling. The October 26 first-line data and the 2027 DLLEVATE interim are the events that will decide whether that story holds. Until then, cash use and Chinese pricing are the numbers to track. --- Source page: https://aibio.space/companies/zai-lab/desk-view/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Zai Lab desk view: Zai Lab's future now runs through one DLL3 drug", 2026-10-31, https://aibio.space/companies/zai-lab/desk-view/